You are here

MHRA greenlights Bionure protocol to begin clinical trials on multiple sclerosis drug


Biotechnology firm Bionure, a spin-off of Hospital Clinic Barcelona-IDIBAPS and member of CataloniaBio, has got the green light from the British Medicines and Healthcare products Regulatory Agency (MHRA) for its protocol to begin clinical trials on BN201, a neuroprotector and myelin regenerator that curbs the progression of multiple sclerosis. The Bionure team has met with the MHRA to discuss the agency’s guidelines for preclinical results and to adjust the clinical protocol to that country’s regulations.

Photo: Albert G. Zamora, CEO of Bionure and Pablo Villoslada, CSO, at Barcelona's offices (Carlos Montañés, El Periódico).